NICE recommends once-weekly injection for severe blood clotting disorder Efanesoctocog alfa, a once-weekly treatment for patients with severe haemophilia A, removes the need for frequent dosing, owing to its effective bleeding control.…
NICE approves gene-editing sickle cell therapy for NHS in England Exagamglogene autotemcel, also known as exa-cel, is now recommended for NHS use, reversing previous draft guidance.…
New class of anticoagulant found to ‘overwhelmingly’ reduce bleeding events in patients with atrial fibrillation Experts say the results of this “exciting” two-year study of abelacimab “add to the growing evidence that inhibition of factor XI may preferentially impact thrombosis over haemostasis”.…
Nearly 92% of atrial fibrillation patients in England anticoagulated, says NHS adviser The UK Health Security Agency has achieved the figure five years ahead of its original 2029 target year by offering anticoagulation to nine in ten patients with atrial fibrillation.…
Statin prescribing in England at record high, show NICE data Figures show that atorvastatin prescribing increased from 4.2 million people in 2022/2023 to 5.0 million people in 2023/2024.…
Manufacturer withdraws treatment for sickle cell disease following concern over deaths Pfizer's withdrawal is based on data that suggest “an imbalance in vast-occlusive crises and fatal events which require further assessment”.…
Lipid-lowering therapies for the secondary prevention of cardiovascular disease in primary care An overview of updated guidance relating to the secondary prevention of cardiovascular disease can be applied in practice, considering the availability of newer medications.…
Pharmacists made 150,000 patient interventions during anticoagulant safety audits, report finds The results of the two national audits revealed a significant increase in patients with a yellow anticoagulant alert card, from 66.5% in 2021/2023 to 73.3% in 2023/2024.…
Statins offer cost-effective benefit for older people, study results suggest The researchers found that lifetime use of a standard statin therapy increased quality-adjusted life years by 0.24–0.70 per person.…
First gene-editing therapy recommended by NICE to treat people with beta thalassaemia NHS England said that around 460 patients aged 12 years and over could benefit from the treatment.…
